THCP, HHCPO, H4CBD and others Classified as Narcotics
From June 3, 2024, several new cannabinoids will be officially classified as narcotics in France due to the serious risks and potential for addiction associated with their consumption. This measure aims to protect public health in the face of increasing reports of serious effects due to these substances. The Centers for Evaluation and Information on Pharmacodependence-Addictovigilance (CEIP-A) have recorded several cases of serious poisoning, thus justifying this decision.
Which cannabinoids are affected by this decision?
Semisynthetic cannabinoids
Semisynthetic cannabinoids are natural substances that have been chemically modified. The main cannabinoids in this category included in the new regulations are:
- H4-CBD
- H2-CBD
Benzo[c]chromene-based cannabinoid derivatives
These cannabinoids, formed from a specific chemical nucleus, are also affected. The list excludes CBN (cannabinol) but includes:
- HHC (Hexahydrocannabinol)
- HHCO (HHC-Acetate)
- HHCP (Hexahydrocannabiphorol)
- HHCPO (HHCP-Acetate)
- THCP (Tetrahydrocannabiphorol)
- THCA (Tetrahydrocannabinolic Acid)
Synthetic cannabinoids
Synthetic cannabinoids, created purely in laboratories, are also under increased surveillance. Substances added to the list of narcotics include:
- 5F-Cumyl-Pegaclone (5F-SGT-151)
- Cumyl-CH-Megaclone (SGT-270)
- 7APAICA
- 5F-7APAICA
- Cumyl-P7AICA
- 5F-Cumyl-P7AICA
- BZO-Hexoxizid (MDA-19)
- BZO-Poxizid (5C-MDA-19)
Why are these substances banned?
Health risks
Consuming these cannabinoids can cause immediate and potentially serious effects, such as:
- Vomiting
- Loss of consciousness
- Coma
- Convulsions
- Paranoia and anxiety
- High blood pressure
- Tachycardia
- Chest pain that may suggest a heart attack
- Renal failure
These effects, often more intense than those caused by THC (the psychoactive component of cannabis), may require emergency medical attention. The danger of these products is exacerbated by their high concentration of cannabinoids, often unknown to the consumer.
Potential for addiction
These products pose a significant risk of dependence, increasing the likelihood of regular and problematic use.
Uncertain composition
Consumers should be aware that the composition of products containing these cannabinoids may not match that indicated on the packaging. This adds an additional risk related to the ingestion of higher doses than intended.
Surveillance and prevention measures
In collaboration with CEIP-A, we maintain continuous monitoring of new cannabinoids appearing on the market and their effects on health. This vigilance is essential to anticipate and respond to emerging threats related to these substances.
Forms of consumption and distribution
These cannabinoids are often sold online and in CBD stores, in different forms:
- Oil
- Resin
- Grass
- Spray
- Gummies
- E-liquids
They can be ingested, vaped or smoked, which influences the intensity and speed of the effects felt.
Conclusion
The decision to classify these cannabinoids as narcotics is a crucial public health measure to prevent the serious risks associated with their use. We encourage potential consumers to stay informed and avoid the use of these dangerous substances. In case of doubt or need for assistance, it is essential to contact health professionals or emergency services.
For more information, please visit our website ama-prevention.fr and consult the ANSM for any questions or reports. Together, let's protect our health and that of our community.
